HONG KONG, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Nano Labs Ltd (Nasdaq: NA) (“we,” the “Company” or “Nano Labs”), a leading Web 3.0 infrastructure and product solution provider, today announced continued progress in its strategic BNB reserve initiative, including the completion of a new round of BNB acquisitions.
HONG KONG, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Nano Labs Ltd (Nasdaq: NA) (“we,” the “Company” or “Nano Labs”), a leading Web 3.0 infrastructure and product solution provider, announced that its Chairman and Chief Executive Officer, Mr. Jianping Kong, has acquired 480,000 class A ordinary shares through open market transactions using personal funds in August. This follows two previous share purchases by Mr. Kong in May and September 2024. These transactions were conducted in strict adherence to the Company’s internal trading policies and is in full compliance with all applicable laws and regulations.
HONG KONG, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Nano Labs Ltd (Nasdaq: NA) (“we,” the “Company” or “Nano Labs”), a leading Web 3.0 infrastructure and product solution provider, announced that it has entered into an At The Market Offering Agreement (the “Sales Agreement”) with Maxim Group LLC as sole sales agent to sell its shares of Class A Ordinary Shares par value $0.002 per share (the “Class A Ordinary Share” or the “Shares”), from time to time in an at the market offering (the “Offering”). Pursuant to the Prospectus Supplement (as defined below) and accompanying base prospectus, we may offer and sell the Class A Ordinary Shares from time to time under the Sales Agreement having an aggregate offering price of up to $45,000,000 in the Offering.
HONG KONG, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Nano Labs Ltd (Nasdaq: NA) (“we,” the “Company” or “Nano Labs”), a leading Web 3.0 infrastructure and product solution provider, today announced its unaudited financial results as of June 30, 2025 and for the first half of 2025 then ended.
HONG KONG, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Nano Labs Ltd (Nasdaq: NA) (“we,” the “Company” or “Nano Labs”), a leading Web 3.0 infrastructure and product solution provider, today announced that it will report its unaudited financial results for the six months ended June 30, 2025 before the U.S. market opens on Friday, August 15, 2025.
- The Phase I trial evaluates the safety, tolerability and preliminary efficacy of ASC50 for the treatment of psoriasis. - Preclinical data, including higher oral exposure, longer half-life and strong efficacy, support ASC50 as a potential best-in-class once-daily oral agent for the...
